SCHEMBL1521667

SCHEMBL1521667

CNc1cc(Cl)ncc1CO

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDXK O00764 2/20 0.38
RECQL P46063 1/20 0.36
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 2/20 0.34
HSD17B10 Q99714 1/20 0.34
POLQ O75417 1/20 0.33
DPP4 P27487 1/20 0.33
LMNA P02545 2/20 0.32
SHBG P04278 1/20 0.32
NPC1 O15118 1/20 0.31
POLB P06746 1/20 0.31
RAB9A P51151 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
AOX1 Q06278 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29765350 1.00 PDXK (0.38) PDXKRECQLKDM4EALDH1A1HPGD
SCHEMBL4281181 0.82 PDXK (0.36) PDXKRECQLKDM4EALDH1A1HPGD
SCHEMBL29848036 0.82 PDXK (0.36) PDXKRECQLKDM4EALDH1A1HPGD
SCHEMBL15110275 0.81 PDXK (0.35) PDXKRECQLKDM4EALDH1A1HPGD
SCHEMBL1521720 0.81 PDXK (0.35) PDXKRECQLKDM4EALDH1A1HPGD
SCHEMBL29847501 0.81 PDXK (0.35) PDXKRECQLKDM4EALDH1A1HPGD
SCHEMBL17119688 0.79 CYP2C19 (0.39) PDXKRECQLKDM4EALDH1A1LMNA
SCHEMBL15413180 0.79 PDXK (0.33) PDXKKDM4EALDH1A1HPGDHSD17B10
SCHEMBL23141924 0.78 PDXK (0.33) PDXKRECQLKDM4EALDH1A1HPGD
SCHEMBL17119662 0.78 JAK2 (0.33) PDXKRECQLPOLQLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624032-B2 Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases UNIVERSITY OF HOUSTON SYSTEM (US) 2026-05-12 US disclosed
US-12516055-B2 Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions TRUSTEES OF TUFTS COLLEGE (US) 2026-01-06 US disclosed
WO-2025217320-A1 INHIBITORS OF RIPK3 AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2025-10-16 WO disclosed
EP-4480485-A2 PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS University of Houston System (US) 2024-12-25 EP disclosed
US-20240327403-A1 PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES UNIVERSITY OF HOUSTON SYSTEM (US) 2024-10-03 US disclosed
EP-3968991-B1 PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS UNIV HOUSTON SYSTEM (US) 2024-07-31 EP disclosed
US-12012402-B2 Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases UNIVERSITY OF HOUSTON SYSTEM (US) 2024-06-18 US disclosed
US-11649247-B2 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors ELI LILLY AND COMPANY (US) 2023-05-16 US disclosed
US-11649247-B2 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors ELI LILLY AND COMPANY (US) 2023-05-16 US disclosed
US-11649247-B2 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors ELI LILLY AND COMPANY (US) 2023-05-16 US disclosed
US-7449582-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2008-11-11 US disclosed
EP-1673343-A4 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-09-10 EP disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed
WO-2008051757-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-05-02 WO disclosed
WO-2008033999-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-03-20 WO disclosed
EP-1673343-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-06-28 EP disclosed
US-20050187230-A1 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2005-08-25 US disclosed
WO-2005034869-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11649247-B2 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors IDH2, IDH1, IDH3B PDXK 8/4885RECQL 436/4885KDM4E 384/4885
US-20240327403-A1 PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES RIPK2, RIPK1, RIPK4 PDXK 16/4885RECQL 3734/4885KDM4E 1806/4885
US-20050187230-A1 Compounds and compositions as protein kinase inhibitors FYN, LCK, SRC PDXK 881/4885RECQL 4200/4885KDM4E 1492/4885
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC PDXK 854/4885RECQL 4004/4885KDM4E 1572/4885
US-12012402-B2 Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases RIPK2, RIPK1, RIPK4 PDXK 16/4885RECQL 3734/4885KDM4E 1806/4885
US-12624032-B2 Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases RIPK2, RIPK1, RIPK4 PDXK 41/4885RECQL 3014/4885KDM4E 851/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 PDXK 130/4885RECQL 1477/4885KDM4E 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.